The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud.

Eidos Therapeutics, Inc. EIDX will issue 6.25 million shares between $15 and $17 Wednesday on the Nasdaq. The clinical-stage pharmaceutical is developing a Phase 2 therapy for transthyretin amyloidosis.

Aptinyx Inc. APTX will issue more than 5.3 million shares between $14 and $16 Thursday on the Nasdaq. The spinoff of an Allergan plc AGN-acquired biopharma develops therapies for neurologic disorders, including fibromyalgia and post-traumatic stress disorder.

Avrobio, Inc. AVRO will issue more than 4.4 million shares between $16 and $18 Thursday on the Nasdaq. The gene therapy developer is advancing single-dose treatments for gaucher, pompe, cystinosis, fabry and lysosomal storage disorders.

Electrocore, LLC ECOR will issue more than 4.3 million shares between $14 and $16 Thursday on the Nasdaq. The biotech company develops proprietary, non-invasive vagus nerve stimulation therapies to treat neurological and rheumatological conditions.

Essential Properties Realty Trust, Inc. EPRT will issue 32.5 million shares between $14 and $17 Thursday on the New York Stock Exchange. The New Jersey company acquires and manages single-tenant business properties with a portfolio spanning 44 states.

I3 Verticals, Inc. IIIV will issue nearly 6.7 million shares between $11 and $13 Thursday on the Nasdaq. The tech company provides business solutions supporting event management, loyalty programs, school operations, online payments, payment processing and rental properties.

Kezar Life Sciences, Inc. KZR will issue nearly 4.7 million shares between $14 and $16 Thursday on the Nasdaq. The clinical-stage biotech firm develops molecular therapeutics to treat autoimmunity and cancer.

Magenta Therapeutics, Inc. MGTA will issue nearly 6.7 million shares between $14 and $16 Thursday on the Nasdaq. Magenta is developing therapeutics to improve patient preparation, stem cell expansion, stem cell harvesting and post-transplant recovery.

Xeris Pharmaceuticals Inc XERS will issue 5 million shares between $14 and $16 Thursday on the Nasdaq. Based in Chicago, the specialty pharmaceutical company develops and commercialize injectable therapies for hypoglycemia, congenital hyperinsulinism, acute repetitive seizures and more.

Autolus Therapeutics Ltd AUTL will issue more than 7.8 million shares between $15 and $17 Friday on the Nasdaq. The T-cell therapy developer targets hematological cancers and solid tumors.

Dermadoctor, LLC DDOC will issue nearly 1.9 million shares between $7 and $9 Friday on the Nasdaq. Dermadoctor develops skin care treatments for acne, eczema, rosacea and other conditions.

Related Links:

5 Reasons Why 2018 Could Be Good For IPO ETFs

3 Tech IPOs We Want In 2018